Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ALX Oncology Holdings Inc. (ALXO)
USD2.01
+0.01 (+0.50%)
US NASDAQ Healthcare Biotechnology
Address
323 Allerton Avenue 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Jason Lettmann
Website
alxoncology.com
IPO
2020-07-17
CIK 1810182 ISIN US00166B1052
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.01
+0.01 (+0.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.45
Float Shares
35.13M
Free Float %
64.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.40% | +7.41% | +16.00% | -8.14% | +66.39% | +79.65% | +322.04% | -68.58% | -96.14% | -93.23% | -93.23% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
2.01
Low
4.00
+99.0%
Consensus
4.00
+99.0%
Median
4.00
+99.0%
High
4.00
+99.0%
DCF (Unlevered)
0.13
-93.7%
DCF (Levered)
0.21
-89.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
4.00
+99.0%
|
| All Time | 7 |
17.07
+749.3%
|
Quality scores
Altman Z-Score
-4.17
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+26.4% Q1'26: +43.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -467.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.8% ★ Q1'26: +1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 5 Rev. Ana. 6 EPS Ana. |
Dec 2029 2 Rev. Ana. 4 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.18M
est: 1.16M (+1.9%)
|
—
est: 168.9K (-100.0%)
|
—
est: 1.16M (-100.0%)
|
—
est: 625.0K (-100.0%)
|
4.60M
4.60M – 4.60M
+636.0% YoY
|
5.35M
5.35M – 5.35M
+16.3% YoY
|
54.50M
54.50M – 54.50M
+918.7% YoY
|
179.90M
179.90M – 179.90M
+230.1% YoY
|
70.00M
70.00M – 70.00M
-61.1% YoY
|
| EBITDA |
-43.46M
est: 696.0K (-6,344.4%)
|
-83.42M
est: 101.3K (-82,438.1%)
|
-132.25M
|
-99.39M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-43.66M
est: 696.0K (-6,373.4%)
|
-83.47M
est: 101.3K (-82,488.4%)
|
-133.12M
|
-100.09M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-45.74M
est: -97.31M (+53.0%)
|
-83.46M
est: -100.91M (+17.3%)
|
-134.85M
est: -149.76M (+10.0%)
|
-101.70M
est: -98.32M (-3.4%)
|
-33.70M
-34.75M – -32.65M
+65.7% YoY
|
-31.74M
-33.60M – -29.87M
+5.8% YoY
|
-33.61M
-47.17M – -20.05M
-5.9% YoY
|
-41.99M
-41.99M – -41.99M
-24.9% YoY
|
-36.76M
-36.76M – -36.76M
+12.5% YoY
|
| SGA |
14.81M
est: 3.83M (+286.2%)
|
23.39M
est: 558.2K (+4,089.4%)
|
26.09M
|
23.85M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.28
est: -1.87 (+31.4%)
|
-2.07
est: -1.93 (-7.0%)
|
-2.58
est: -2.76 (+6.4%)
|
-1.90
est: -1.82 (-4.3%)
|
-0.62
-0.65 – -0.61
+66.1% YoY
|
-0.59
-0.63 – -0.56
+4.3% YoY
|
-0.65
-0.88 – -0.37
-10.1% YoY
|
-0.78
-0.78 – -0.78
-20.1% YoY
|
-0.69
-0.69 – -0.69
+12.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-78.13M
OE per share TTM
-1.28
Owner's Yield
-35.92%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
600.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
2.18M
Insider transactions (90d)
0
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Robert Adelman | 9.80M | 26.90% | 99.4K | 9.70M | 99.4K | 9.70M | IN | — | 2020-10-01 | ↗ |
| 2 | Corey Goodman | 9.70M | 26.60% | — | 9.70M | — | 9.70M | IN | — | 2020-10-01 | ↗ |
| 3 | venBio Global Strategic Fund II, L.P. | 5.27M | 14.40% | — | 5.27M | — | 5.27M | PN | — | 2020-10-01 | ↗ |
| 4 | venBio Global Strategic GP II, L.P. | 5.27M | 14.40% | — | 5.27M | — | 5.27M | PN | — | 2020-10-01 | ↗ |
| 5 | Jeremy C. Green | 4.99M | 9.60% | — | 4.99M | — | 4.99M | HC, IN | United Kingdom | 2023-10-16 | ↗ |
| 6 | Redmile Group, LLC | 4.99M | 9.60% | — | 4.99M | — | 4.99M | IA, OO | Delaware | 2023-10-16 | ↗ |
| 7 | Henry A. Plain, Jr. | 4.72M | 12.90% | — | 4.72M | — | 4.72M | IN | — | 2020-07-31 | ↗ |
| 8 | Jean M. George | 4.72M | 12.90% | — | 4.72M | — | 4.72M | IN | — | 2020-07-31 | ↗ |
| 9 | Michael A. Carusi | 4.72M | 12.90% | — | 4.72M | — | 4.72M | IN | — | 2020-07-31 | ↗ |
| 10 | venBio Global Strategic Fund, L.P. | 4.43M | 12.10% | — | 4.43M | — | 4.43M | PN | — | 2020-10-01 | ↗ |
| 11 | venBio Global Strategic GP, L.P. | 4.43M | 12.10% | — | 4.43M | — | 4.43M | PN | — | 2020-10-01 | ↗ |
| 12 | FMR LLC | 4.28M | 10.52% | 4.28M | — | 4.28M | — | HC | Delaware | 2022-08-10 | ↗ |
| 13 | Vivo Capital IX, LLC | 4.03M | 11.10% | 4.03M | — | 4.03M | — | OO | Delaware | 2020-07-29 | ↗ |
| 14 | Wellington Group Holdings LLP | 3.73M | 9.21% | — | 3.42M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 15 | Wellington Investment Advisors Holdings LLP | 3.73M | 9.21% | — | 3.42M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 16 | Wellington Management Group LLP | 3.73M | 9.21% | — | 3.42M | — | — | HC | Massachusetts | 2022-02-04 | ↗ |
| 17 | Redmile Biopharma Investments III, L.P. | 3.68M | 7.10% | — | 3.68M | — | 3.68M | PN | Delaware | 2023-10-16 | ↗ |
| 18 | Wellington Management Company LLP | 3.59M | 8.87% | — | 3.41M | — | — | IA | Delaware | 2022-02-04 | ↗ |
| 19 | Israel A. Englander | 2.96M | 5.60% | — | 2.96M | — | 2.96M | IN | Delaware | 2024-08-13 | ↗ |
| 20 | Millennium Group Management LLC | 2.96M | 5.60% | — | 2.96M | — | 2.96M | OO | Delaware | 2024-08-13 | ↗ |
| 21 | Millennium Management LLC | 2.96M | 5.60% | — | 2.96M | — | 2.96M | OO | Delaware | 2024-08-13 | ↗ |
| 22 | Cormorant Global Healthcare Master Fund, LP | 2.63M | 5.28% | — | 2.63M | — | 2.63M | PN | Cayman Islands | 2023-10-13 | ↗ |
| 23 | LSV Associates, LLC | 2.58M | 7.10% | 2.58M | — | 2.58M | — | OO | — | 2020-07-31 | ↗ |
| 24 | Lightstone Ventures, L.P. | 2.27M | 6.20% | 2.27M | — | 2.27M | — | PN | — | 2020-07-31 | ↗ |
| 25 | OrbiMed Capital LLC | 2.27M | 5.60% | 2.27M | — | 2.27M | — | IA | Delaware | 2023-02-14 | ↗ |
| 26 | Jason W. Lettmann | 2.25M | 6.20% | 107.2K | 2.14M | 107.2K | 2.14M | IN | — | 2020-07-31 | ↗ |
| 27 | LSV Associates II, LLC | 2.14M | 5.90% | 2.14M | — | 2.14M | — | OO | — | 2020-07-31 | ↗ |
| 28 | Lightstone Ventures II, L.P. | 2.02M | 5.50% | 2.02M | — | 2.02M | — | PN | — | 2020-07-31 | ↗ |
| 29 | OrbiMed Advisors LLC | 605.0K | 1.50% | — | 605.0K | — | — | IA | Delaware | 2023-02-14 | ↗ |
| 30 | Lightstone Ventures (A), L.P. | 309.2K | 0.80% | 309.2K | — | 309.2K | — | PN | — | 2020-07-31 | ↗ |
| 31 | Vivo Opportunity, LLC | 185.5K | 0.50% | 185.5K | — | 185.5K | — | OO | Delaware | 2020-07-29 | ↗ |
| 32 | Lightstone Ventures II (A), L.P. | 120.2K | 0.30% | 120.2K | — | 120.2K | — | PN | — | 2020-07-31 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-52 vs prev Q
New positions
0
Closed positions
46
Increased
2
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VENBIO PARTNERS LLC | 9.70M +— (+0.0%) | 10.96M -6.8M (-38.3%) | 18.10% -0.045 pp | 5.07% -4.995 pp | USD37.74 -97.0% | 22 qtrs — |
| 2 | REDMILE GROUP, LLC | 3.26M -68.3K (-2.0%) | 3.69M -2.4M (-39.5%) | 6.09% -0.143 pp | 0.27% -0.322 pp | USD20.01 -94.4% | 22 qtrs — |
| 3 | ALMITAS CAPITAL LLC | 2.54M +— (+0.0%) | 2.87M -1.8M (-38.3%) | 4.74% -0.012 pp | 0.63% -0.431 pp | USD1.03 +9.7% | 5 qtrs — |
| 4 | VANGUARD GROUP INC | 1.63M +102.3K (+6.7%) | 1.84M -954.4K (-34.1%) | 3.04% +0.184 pp | 0.00% +0.000 pp | USD32.40 -96.5% | 22 qtrs — |
| 5 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.42M +627.1K (+78.8%) | 1.61M +151.6K (+10.4%) | 2.66% +1.167 pp | 0.01% +0.001 pp | USD1.52 -25.7% | 2 qtrs — |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 1.37M +153.4K (+12.6%) | 1.55M -681.0K (-30.5%) | 2.57% +0.281 pp | 0.00% -0.001 pp | USD1.52 -25.7% | 6 qtrs — |
| 7 | UBS GROUP AG | 866.0K +693.4K (+401.8%) | 978.6K +662.8K (+209.9%) | 1.62% +1.294 pp | 0.00% +0.000 pp | USD1.29 -12.4% | 13 qtrs — |
| 8 | TWO SIGMA ADVISERS, LP | 710.4K -9.4K (-1.3%) | 802.8K -514.5K (-39.1%) | 1.33% -0.021 pp | 0.00% -0.001 pp | USD2.10 -46.2% | 17 qtrs — |
| 9 | TWO SIGMA INVESTMENTS, LP | 640.2K +33.5K (+5.5%) | 723.4K -386.8K (-34.8%) | 1.19% +0.060 pp | 0.00% -0.001 pp | USD3.69 -69.4% | 9 qtrs — |
| 10 | BANK OF AMERICA CORP /DE/ | 531.8K +1.0K (+0.2%) | 601.0K -370.4K (-38.1%) | 0.99% -0.001 pp | 0.00% +0.000 pp | USD1.61 -29.8% | 22 qtrs — |
| 11 | BANK OF MONTREAL /CAN/ | 474.8K +— (+0.0%) | 536.5K -332.3K (-38.3%) | 0.89% -0.002 pp | 0.00% 0.000 pp | USD1.67 -32.3% | 5 qtrs — |
| 12 | BLACKROCK, INC. | 450.4K +2.7K (+0.6%) | 509.0K -310.3K (-37.9%) | 0.84% +0.003 pp | 0.00% +0.000 pp | USD1.82 -37.9% | 6 qtrs — |
| 13 | DEKABANK DEUTSCHE GIROZENTRALE | 41.0K +— (+0.0%) | 508.0K +5.0K (+1.0%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD46.17 -97.6% | 21 qtrs — |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 423.1K +258.6K (+157.2%) | 478.1K +177.1K (+58.8%) | 0.79% +0.482 pp | 0.00% +0.000 pp | USD1.12 +0.9% | 17 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 353.7K +1.4K (+0.4%) | 399.8K -245.2K (-38.0%) | 0.66% +0.001 pp | 0.00% +0.000 pp | USD26.62 -95.8% | 22 qtrs — |
| 16 | JANE STREET GROUP, LLC | 186.0K +5.5K (+3.1%) | 210.1K -120.0K (-36.4%) | 0.35% +0.010 pp | 0.00% +0.000 pp | USD0.44 +156.8% | 9 qtrs — |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 151.0K +38.0K (+33.6%) | 170.7K -36.2K (-17.5%) | 0.28% +0.070 pp | 0.00% +0.000 pp | USD1.65 -31.5% | 12 qtrs — |
| 18 | NORTHERN TRUST CORP | 149.1K +53.9K (+56.7%) | 168.5K -5.7K (-3.3%) | 0.28% +0.100 pp | 0.00% +0.000 pp | USD14.35 -92.1% | 22 qtrs — |
| 19 | STATE STREET CORP | 124.2K +12.3K (+11.0%) | 140.4K -64.5K (-31.5%) | 0.23% +0.022 pp | 0.00% +0.000 pp | USD20.80 -94.6% | 22 qtrs — |
| 20 | — | 117.8K +117.8K (+100.0%) | 133.1K +133.1K (+100.0%) | 0.22% +0.220 pp | 0.10% +0.101 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 21 | BANK OF NOVA SCOTIA | 105.9K +— (+0.0%) | 119.6K -74.1K (-38.3%) | 0.20% -0.001 pp | 0.00% 0.000 pp | USD1.66 -31.9% | 5 qtrs — |
| 22 | MILLENNIUM MANAGEMENT LLC | 100.0K +59.1K (+144.5%) | 113.0K +38.2K (+51.0%) | 0.19% +0.110 pp | 0.00% +0.000 pp | USD1.42 -20.4% | 2 qtrs — |
| 23 | GSA CAPITAL PARTNERS LLP | 92.7K +4.5K (+5.1%) | 105.0K -56.0K (-34.8%) | 0.17% +0.008 pp | 0.01% -0.004 pp | USD0.55 +105.5% | 3 qtrs — |
| 24 | IEQ CAPITAL, LLC | 92.2K +— (+0.0%) | 104.2K -64.6K (-38.3%) | 0.17% 0.000 pp | 0.00% 0.000 pp | USD1.83 -38.3% | 2 qtrs — |
| 25 | MORGAN STANLEY | 83.8K -1.5K (-1.8%) | 94.6K -61.4K (-39.4%) | 0.16% -0.003 pp | 0.00% +0.000 pp | USD2.94 -61.6% | 22 qtrs — |
| 26 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 76.1K +40.1K (+111.3%) | 86.0K +20.1K (+30.5%) | 0.14% +0.075 pp | 0.00% +0.000 pp | USD1.46 -22.6% | 2 qtrs — |
| 27 | CITADEL ADVISORS LLC | 66.9K +9.4K (+16.3%) | 75.6K -29.6K (-28.2%) | 0.12% +0.017 pp | 0.00% +0.000 pp | USD2.09 -45.9% | 20 qtrs — |
| 28 | NAN FUNG TRINITY (HK) LTD | 42.0K +— (+0.0%) | 47.4K -29.4K (-38.3%) | 0.08% 0.000 pp | 0.00% -0.004 pp | USD0.42 +169.0% | 3 qtrs — |
| 29 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 38.0K -81.0 (-0.2%) | 41.0K -28.6K (-41.1%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD4.98 -77.3% | 7 qtrs — |
| 30 | CALLAN FAMILY OFFICE, LLC | 28.3K +8.5K (+43.1%) | 32.0K -4.2K (-11.6%) | 0.05% +0.016 pp | 0.00% -0.001 pp | USD0.63 +79.4% | 3 qtrs — |
| 31 | MARSHALL WACE, LLP | 26.4K -13.2K (-33.4%) | 29.8K -42.6K (-58.9%) | 0.05% -0.025 pp | 0.00% +0.000 pp | USD0.62 +82.3% | 9 qtrs — |
| 32 | HC ADVISORS, LLC | 23.9K +2.1K (+9.4%) | 27.0K -13.0K (-32.5%) | 0.04% +0.004 pp | 0.02% -0.009 pp | USD1.47 -23.1% | 6 qtrs — |
| 33 | LIDO ADVISORS, LLC | 13.2K +— (+0.0%) | 24.2K +— (+0.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD1.67 -32.3% | 5 qtrs — |
| 34 | POINT72 ASSET MANAGEMENT, L.P. | 20.2K +20.2K (+100.0%) | 22.8K +22.8K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 35 | JSF FINANCIAL, LLC | 17.5K +— (+0.0%) | 19.8K -12.3K (-38.3%) | 0.03% 0.000 pp | 0.00% -0.003 pp | USD1.67 -32.3% | 5 qtrs — |
| 36 | GOLDMAN SACHS GROUP INC | 17.3K -1.3K (-7.2%) | 19.5K -14.5K (-42.7%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD10.21 -88.9% | 22 qtrs — |
| 37 | NINE MASTS CAPITAL LTD | 15.5K +15.5K (+100.0%) | 17.5K +17.5K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.003 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 38 | MONETA GROUP INVESTMENT ADVISORS LLC | 15.2K +— (+0.0%) | 17.2K -10.6K (-38.3%) | 0.03% 0.000 pp | 0.00% 0.000 pp | USD1.67 -32.3% | 5 qtrs — |
| 39 | COMMONWEALTH EQUITY SERVICES, LLC | 15.1K -5.5K (-26.6%) | 17.1K -20.9K (-55.1%) | 0.03% -0.010 pp | 0.00% +0.000 pp | USD0.82 +37.8% | 6 qtrs — |
| 40 | VIRTU FINANCIAL LLC | 13.7K +13.7K (+100.0%) | 15.0K +15.0K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.001 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 41 | FMR LLC | 13.0K +— (+0.0%) | 14.7K -9.1K (-38.3%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD20.35 -94.4% | 22 qtrs — |
| 42 | ABEL HALL, LLC | 12.6K +— (+0.0%) | 14.2K -8.8K (-38.2%) | 0.02% 0.000 pp | 0.00% -0.006 pp | USD0.42 +169.0% | 5 qtrs — |
| 43 | BARCLAYS PLC | 10.5K -49.0K (-82.3%) | 11.9K -96.4K (-89.0%) | 0.02% -0.092 pp | 0.00% +0.000 pp | USD2.26 -50.0% | 16 qtrs — |
| 44 | HSBC HOLDINGS PLC | 10.1K -712.0 (-6.6%) | 11.6K -7.5K (-39.3%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD4.58 -75.3% | 10 qtrs — |
| 45 | SIMPLEX TRADING, LLC | 3.6K +3.6K (+100.0%) | 4.0K +4.0K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD1.13 +0.0% | 1 qtrs NEW |
| 46 | TOWER RESEARCH CAPITAL LLC (TRC) | 3.1K -696.0 (-18.1%) | 3.6K -3.5K (-49.5%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD4.52 -75.0% | 22 qtrs — |
| 47 | NISA INVESTMENT ADVISORS, LLC | 1.1K +— (+0.0%) | 1.3K -774.0 (-38.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.46 -82.5% | 17 qtrs — |
| 48 | BRADLEY & CO. PRIVATE WEALTH MANAGEMENT, LLC | 1.0K +— (+0.0%) | 1.1K -700.0 (-38.3%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD1.67 -32.3% | 5 qtrs — |
| 49 | ROYAL BANK OF CANADA | 963.00 -140.0 (-12.7%) | 1.0K -1.0K (-50.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.05 -44.9% | 21 qtrs — |
| 50 | GROUP ONE TRADING, L.P. | 518.00 +518.0 (+100.0%) | 585.00 +585.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.13 +0.0% | 6 qtrs — |
| 51 | BNP PARIBAS ARBITRAGE, SNC | 480.00 +— (+0.0%) | 542.00 -336.0 (-38.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.67 -32.3% | 5 qtrs — |
| 52 | SBI SECURITIES CO., LTD. | 412.00 -10.0 (-2.4%) | 466.00 -306.0 (-39.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.52 +117.3% | 5 qtrs — |
| 53 | PNC FINANCIAL SERVICES GROUP, INC. | 100.00 +— (+0.0%) | 113.00 -70.0 (-38.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.07 -45.4% | 18 qtrs — |
| 54 | JPMORGAN CHASE & CO | 99.00 -61.8K (-99.8%) | 112.00 -113.2K (-99.9%) | 0.00% -0.116 pp | 0.00% +0.000 pp | USD3.72 -69.6% | 22 qtrs — |
| 55 | OPTIVER HOLDING B.V. | 27.00 -1.0 (-3.6%) | 31.00 -20.0 (-39.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.81 -37.6% | 2 qtrs — |
| 56 | AMERIPRISE FINANCIAL INC | — -652.9K (-100.0%) | — -1.2M (-100.0%) | 0.00% -1.222 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 57 | PRIVIUM FUND MANAGEMENT B.V. | — -509.1K (-100.0%) | — -931.6K (-100.0%) | 0.00% -0.953 pp | 0.00% -0.168 pp | USD— | 7 qtrs SOLD |
| 58 | QUBE RESEARCH & TECHNOLOGIES LTD | — -16.9K (-100.0%) | — -31.0K (-100.0%) | 0.00% -0.032 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 59 | SRS CAPITAL ADVISORS, INC. | — -2.0 (-100.0%) | — -3.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 60 | HRT FINANCIAL LP | — -22.5K (-100.0%) | — -41.0K (-100.0%) | 0.00% -0.042 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 61 | FEDERATED HERMES, INC. | — -2.4K (-100.0%) | — -4.3K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 16 qtrs SOLD |
| 62 | EVERSOURCE WEALTH ADVISORS, LLC | — -499.0 (-100.0%) | — -913.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 63 | CITIGROUP INC | — -2.3K (-100.0%) | — -4.2K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 22 qtrs SOLD |
| 64 | AQR CAPITAL MANAGEMENT LLC | — -10.8K (-100.0%) | — -19.8K (-100.0%) | 0.00% -0.020 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 65 | XTX TOPCO LTD | — -26.6K (-100.0%) | — -48.7K (-100.0%) | 0.00% -0.050 pp | 0.00% -0.003 pp | USD— | 12 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 40 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.56% | 122.7K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.05% | 768.8K | 0.60% |
| 3 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.04% | 371.4K | 0.20% |
| 4 | iShares Russell 2000 Growth ETF IWO | 0.01% | 2.16M | 0.24% |
| 5 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 215.7K | 0.30% |
| 6 | Global X - Russell 2000 ETF RSSL | 0.01% | 107.2K | 0.08% |
| 7 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 23.2K | 0.25% |
| 8 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 3.9K | 0.39% |
| 9 | iShares Russell 2000 ETF IWM | 0.01% | 5.63M | 0.19% |
| 10 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 36.8K | 0.36% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
900.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+900,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Knight Jeff E. | Officer | A-Award | A | Stock option (right to buy) | 800,000 | 1.68 | 1.34M | 800,000 | D | ↗ |
| 2026-04-16 | Klencke Barbara | Officer | A-Award | A | Stock option (right to buy) | 100,000 | 1.68 | 168.0K | 100,000 | D | ↗ |
| 2026-04-13 | Knight Jeff E. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-19 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 903 | 2.17 | 2.0K | 86,805 | D | ↗ |
| 2026-03-19 | Lettmann Jason | Director / Officer | S-Sale | D | Common Stock | 12,311 | 2.17 | 26.7K | 293,609 | D | ↗ |
| 2026-03-03 | Klencke Barbara | Officer | A-Award | A | Stock option (right to buy) | 700,000 | 2.07 | 1.45M | 700,000 | D | ↗ |
| 2026-02-25 | Klencke Barbara | Officer | — | — | Common Stock | 0 | 0.00 | — | 60,000 | I | ↗ |
| 2026-02-18 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 565 | 2.27 | 1.3K | 87,708 | D | ↗ |
| 2026-02-17 | Lettmann Jason | Director / Officer | F-InKind | D | Common Stock | 2,201 | 2.27 | 5.0K | 305,920 | D | ↗ |
| 2026-02-02 | GOODMAN COREY S | Director / 10% Owner | P-Purchase | A | Common Stock | 3,184,713 | 1.57 | 5.00M | 8,453,038 | I | ↗ |
| 2026-01-26 | Shantharam Harish | Officer | A-Award | A | Stock option (right to buy) | 303,000 | 1.48 | 448.4K | 303,000 | D | ↗ |
| 2026-01-26 | Pinto Shelly | Officer | A-Award | A | Stock option (right to buy) | 192,000 | 1.48 | 284.2K | 192,000 | D | ↗ |
| 2026-01-26 | Lettmann Jason | Director / Officer | A-Award | A | Stock option (right to buy) | 912,000 | 1.48 | 1.35M | 912,000 | D | ↗ |
| 2026-01-20 | Takimoto Chris H | Director | A-Award | A | Stock option (right to buy) | 40,400 | 1.32 | 53.3K | 40,400 | D | ↗ |
| 2026-01-20 | Sandler Alan B. | Director | A-Award | A | Stock option (right to buy) | 10,100 | 1.32 | 13.3K | 10,100 | D | ↗ |
| 2026-01-20 | Hemrajani Rekha | Director | A-Award | A | Stock option (right to buy) | 40,400 | 1.32 | 53.3K | 40,400 | D | ↗ |
| 2026-01-20 | Garland J. Scott | Director | A-Award | A | Stock option (right to buy) | 40,400 | 1.32 | 53.3K | 40,400 | D | ↗ |
| 2026-01-20 | GOODMAN COREY S | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 40,400 | 1.32 | 53.3K | 40,400 | D | ↗ |
| 2026-01-20 | Curran Daniel J. | Director | A-Award | A | Stock Option (right to buy) | 16,833 | 1.32 | 22.2K | 16,833 | D | ↗ |
| 2026-01-06 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 3,925 | 1.11 | 4.4K | 88,273 | D | ↗ |
| 2025-10-14 | Shantharam Harish | Officer | A-Award | A | Employee Stock Option (right to buy) | 198,750 | 1.70 | 337.9K | 198,750 | D | ↗ |
| 2025-10-14 | Pinto Shelly | Officer | A-Award | A | Employee Stock Option (right to buy) | 140,000 | 1.70 | 238.0K | 140,000 | D | ↗ |
| 2025-10-14 | Lettmann Jason | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 597,500 | 1.70 | 1.02M | 597,500 | D | ↗ |
| 2025-09-17 | Lettmann Jason | Director / Officer | P-Purchase | A | Common Stock | 71,163 | 1.08 | 76.9K | 305,121 | D | ↗ |
| 2025-09-17 | Klencke Barbara | Director | A-Award | A | Stock option (right to buy) | 300,000 | 1.05 | 315.0K | 300,000 | D | ↗ |
| 2025-09-16 | Lettmann Jason | Director / Officer | P-Purchase | A | Common Stock | 21,070 | 1.07 | 22.5K | 233,958 | D | ↗ |
| 2025-08-18 | Shantharam Harish | Officer | P-Purchase | A | Common Stock | 75,000 | 0.78 | 58.4K | 75,000 | D | ↗ |
| 2025-08-15 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 611 | 0.64 | 391.28 | 89,198 | D | ↗ |
| 2025-08-15 | Lettmann Jason | Director / Officer | S-Sale | D | Common Stock | 2,382 | 0.64 | 1.5K | 212,888 | D | ↗ |
| 2025-08-12 | Curran Daniel J. | Director | A-Award | A | Stock option (right to buy) | 40,400 | 0.62 | 24.8K | 40,400 | D | ↗ |
| 2025-07-07 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 2,011 | 0.45 | 905.15 | 86,809 | D | ↗ |
| 2025-06-30 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 1,532 | 0.43 | 658.76 | 88,820 | D | ↗ |
| 2025-04-11 | Shantharam Harish | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 0.49 | 61.3K | 125,000 | D | ↗ |
| 2025-04-11 | Sandler Alan B. | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 0.49 | 61.3K | 125,000 | D | ↗ |
| 2025-04-11 | Pinto Shelly | Officer | A-Award | A | Employee Stock Option (right to buy) | 90,000 | 0.49 | 44.1K | 90,000 | D | ↗ |
| 2025-04-11 | Lettmann Jason | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 0.49 | 61.3K | 125,000 | D | ↗ |
| 2025-03-14 | Pinto Shelly | Officer | A-Award | A | Common Stock | 3,000 | 0.00 | — | 90,352 | D | ↗ |
| 2025-03-14 | Lettmann Jason | Director / Officer | A-Award | A | Common Stock | 42,000 | 0.00 | — | 212,270 | D | ↗ |
| 2025-02-19 | Pons Jaume | Officer | S-Sale | D | Common Stock | 1,326 | 1.15 | 1.5K | 579,388 | D | ↗ |
| 2025-02-19 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 550 | 1.15 | 632.61 | 87,352 | D | ↗ |
| 2025-02-19 | Lettmann Jason | Director / Officer | S-Sale | D | Common Stock | 2,159 | 1.15 | 2.5K | 170,270 | D | ↗ |
| 2025-01-21 | Takimoto Chris H | Director | A-Award | A | Common Stock (right to buy) | 40,400 | 1.65 | 66.7K | 40,400 | D | ↗ |
| 2025-01-21 | Shantharam Harish | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-21 | Sandler Alan B. | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 1.65 | 165.0K | 100,000 | D | ↗ |
| 2025-01-21 | Pons Jaume | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 1.65 | 82.5K | 50,000 | D | ↗ |
| 2025-01-21 | Pinto Shelly | Officer | A-Award | A | Employee Stock Option (right to buy) | 112,000 | 1.65 | 184.8K | 112,000 | D | ↗ |
| 2025-01-21 | Lettmann Jason | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 478,000 | 1.65 | 788.7K | 478,000 | D | ↗ |
| 2025-01-21 | Klencke Barbara | Director | — | — | Common Stock | 0 | 0.00 | — | 60,000 | I | ↗ |
| 2025-01-21 | Hemrajani Rekha | Director | A-Award | A | Stock Option (right to buy) | 40,400 | 1.65 | 66.7K | 40,400 | D | ↗ |
| 2025-01-21 | Garland J. Scott | Director | A-Award | A | Common Stock | 40,400 | 1.65 | 66.7K | 40,400 | D | ↗ |
| 2025-01-21 | GOODMAN COREY S | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 40,400 | 1.65 | 66.7K | 40,400 | D | ↗ |
| 2025-01-06 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 2,221 | 1.80 | 4.0K | 87,902 | D | ↗ |
| 2024-12-30 | Pons Jaume | Officer | S-Sale | D | Common Stock | 10,796 | 1.58 | 17.1K | 580,714 | D | ↗ |
| 2024-12-30 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 1,426 | 1.58 | 2.3K | 90,123 | D | ↗ |
| 2024-12-02 | Pinto Shelly | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 1.66 | 249.0K | 150,000 | D | ↗ |
| 2024-12-02 | Lettmann Jason | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.66 | 332.0K | 200,000 | D | ↗ |
| 2024-12-02 | Hemrajani Rekha | Director | P-Purchase | A | Common Stock | 30,000 | 1.55 | 46.4K | 33,000 | D | ↗ |
| 2024-11-18 | Sandler Alan B. | Officer | A-Award | A | Employee Stock Option (right to buy) | 600,000 | 1.22 | 732.0K | 600,000 | D | ↗ |
| 2024-08-14 | Randolph Sophia | Officer | S-Sale | D | Common Stock | 1,365 | 2.58 | 3.5K | 325,711 | — | ↗ |
| 2024-08-14 | Pons Jaume | Officer | S-Sale | D | Common Stock | 1,937 | 2.58 | 5.0K | 591,510 | — | ↗ |
| 2024-08-14 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 564 | 2.58 | 1.5K | 91,549 | — | ↗ |
| 2024-08-14 | Lettmann Jason | Director / Officer | F-InKind | D | Common Stock | 2,191 | 2.58 | 5.7K | 169,429 | — | ↗ |
| 2024-08-14 | GARCIA PETER S | Officer | F-InKind | D | Common Stock | 761 | 2.58 | 2.0K | 121,516 | — | ↗ |
| 2024-08-05 | Sandler Alan B. | Director | A-Award | A | Stock Option (right to buy) | 40,400 | 2.73 | 110.3K | 40,400 | — | ↗ |
| 2024-07-11 | Pons Jaume | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 0.99 | 19.8K | 613,447 | — | ↗ |
| 2024-07-05 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 1,823 | 5.50 | 10.0K | 92,113 | — | ↗ |
| 2024-07-01 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 3,273 | 5.82 | 19.0K | 327,076 | — | ↗ |
| 2024-07-01 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 10,758 | 5.82 | 62.6K | 593,447 | — | ↗ |
| 2024-07-01 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 1,373 | 5.82 | 8.0K | 93,936 | — | ↗ |
| 2024-06-28 | GARCIA PETER S | Officer | F-InKind | D | Common Stock | 1,789 | 6.03 | 10.8K | 122,277 | — | ↗ |
| 2024-06-13 | Hemrajani Rekha | Director | A-Award | A | Stock Option (right to buy) | 20,200 | 8.44 | 170.5K | 20,200 | — | ↗ |
| 2024-06-13 | Garland J. Scott | Director | A-Award | A | Stock Option (right to buy) | 20,200 | 8.44 | 170.5K | 20,200 | — | ↗ |
| 2024-06-13 | GOODMAN COREY S | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,200 | 8.44 | 170.5K | 20,200 | — | ↗ |
| 2024-06-13 | GARCIA PETER S | Officer | P-Purchase | A | Common Stock | 12,000 | 8.53 | 102.3K | 122,348 | — | ↗ |
| 2024-06-04 | Pons Jaume | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 0.99 | 19.8K | 624,205 | — | ↗ |
| 2024-05-13 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 10,203 | 15.82 | 161.4K | 332,146 | — | ↗ |
| 2024-05-06 | Pons Jaume | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 0.99 | 19.8K | 624,205 | — | ↗ |
| 2024-04-16 | Pons Jaume | Director / Officer | M-Exempt | A | Common Stock | 25,846 | 0.99 | 25.6K | 654,205 | — | ↗ |
| 2024-04-04 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 20,000 | 11.15 | 223.0K | 628,359 | — | ↗ |
| 2024-03-14 | Lettmann Jason | Director / Officer | P-Purchase | A | Common Stock | 4,400 | 11.31 | 49.8K | 171,620 | — | ↗ |
| 2024-02-14 | Randolph Sophia | Director / Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 342,349 | — | ↗ |
| 2024-02-14 | Pons Jaume | Director / Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 648,359 | — | ↗ |
| 2024-02-14 | Pinto Shelly | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 93,591 | — | ↗ |
| 2024-02-14 | Lettmann Jason | Director / Officer | A-Award | A | Employee Stock Option | 190,000 | 15.84 | 3.01M | 190,000 | — | ↗ |
| 2024-02-14 | GARCIA PETER S | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 110,348 | — | ↗ |
| 2024-01-04 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 2,717 | 13.60 | 37.0K | 78,591 | — | ↗ |
| 2023-12-29 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 3,128 | 15.04 | 47.0K | 312,349 | — | ↗ |
| 2023-12-29 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 7,179 | 15.04 | 108.0K | 618,359 | — | ↗ |
| 2023-12-29 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 1,631 | 15.04 | 24.5K | 81,308 | — | ↗ |
| 2023-12-29 | GARCIA PETER S | Officer | S-Sale | D | Common Stock | 1,893 | 15.04 | 28.5K | 85,348 | — | ↗ |
| 2023-09-08 | Lettmann Jason | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,200,000 | 4.92 | 5.90M | 1,200,000 | — | ↗ |
| 2023-07-25 | Randolph Sophia | Director / Officer | A-Award | A | Common Stock | 34,000 | 0.00 | — | 315,477 | — | ↗ |
| 2023-07-25 | Pons Jaume | Director / Officer | A-Award | A | Common Stock | 89,000 | 0.00 | — | 625,538 | — | ↗ |
| 2023-07-25 | Pinto Shelly | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 81,713 | — | ↗ |
| 2023-07-25 | GARCIA PETER S | Officer | A-Award | A | Employee Stock Option (right to buy) | 101,000 | 5.86 | 591.9K | 101,000 | — | ↗ |
| 2023-07-06 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 7,345 | 6.52 | 47.9K | 55,713 | — | ↗ |
| 2023-06-30 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 1,605 | 7.34 | 11.8K | 281,477 | — | ↗ |
| 2023-06-30 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 3,208 | 7.34 | 23.5K | 536,538 | — | ↗ |
| 2023-06-30 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 466 | 7.34 | 3.4K | 63,058 | — | ↗ |
| 2023-06-30 | GARCIA PETER S | Officer | S-Sale | D | Common Stock | 887 | 7.34 | 6.5K | 54,738 | — | ↗ |
| 2023-06-20 | Nielsen Jack | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,200 | 8.14 | 164.4K | 20,200 | — | ↗ |
| 2023-06-20 | Lettmann Jason | Director / 10% Owner | A-Award | A | Stock option (right to buy) | 20,200 | 8.14 | 164.4K | 20,200 | — | ↗ |
| 2023-06-20 | Hemrajani Rekha | Director | A-Award | A | Stock Option (right to buy) | 20,200 | 8.14 | 164.4K | 20,200 | — | ↗ |
| 2023-06-20 | Garland J. Scott | Director | A-Award | A | Stock Option (right to buy) | 10,100 | 8.14 | 82.2K | 10,100 | — | ↗ |
| 2023-06-20 | GOODMAN COREY S | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,200 | 8.14 | 164.4K | 20,200 | — | ↗ |
| 2023-06-20 | Canamasas Itziar | Director | A-Award | A | Stock Option (right to buy) | 20,200 | 8.14 | 164.4K | 20,200 | — | ↗ |
| 2023-06-09 | Randolph Sophia | Director / Officer | M-Exempt | A | Common Stock | 6,256 | 4.81 | 30.1K | 283,082 | — | ↗ |
| 2022-12-29 | Randolph Sophia | Officer | S-Sale | D | Common Stock | 1,617 | 11.07 | 17.9K | 270,253 | — | ↗ |
| 2022-12-29 | Pons Jaume | Officer | S-Sale | D | Common Stock | 3,232 | 11.07 | 35.8K | 539,746 | — | ↗ |
| 2022-12-29 | Pinto Shelly | Officer | S-Sale | D | Common Stock | 482 | 11.07 | 5.3K | 62,097 | — | ↗ |
| 2022-12-29 | GARCIA PETER S | Officer | S-Sale | D | Common Stock | 893 | 11.07 | 9.9K | 53,723 | — | ↗ |
| 2022-12-16 | Randolph Sophia | Officer | M-Exempt | A | Common Stock | 25,339 | 4.81 | 121.9K | 271,870 | — | ↗ |
| 2022-11-28 | Garland J. Scott | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-08-05 | Randolph Sophia | Officer | A-Award | A | Employee Stock Option (right to buy) | 123,000 | 0.00 | — | 123,000 | — | ↗ |
| 2022-08-05 | Pons Jaume | Officer | A-Award | A | Employee Stock Option (right to buy) | 244,000 | 0.00 | — | 244,000 | — | ↗ |
| 2022-08-05 | Pinto Shelly | Officer | A-Award | A | Common Stock | 11,000 | 0.00 | — | 62,718 | — | ↗ |
| 2022-08-05 | GARCIA PETER S | Officer | A-Award | A | Common Stock | 29,000 | 0.00 | — | 55,178 | — | ↗ |
| 2022-06-15 | Nielsen Jack | Director | A-Award | A | Stock Option (right to buy) | 12,004 | 0.00 | — | 12,004 | — | ↗ |
| 2022-06-15 | Lettmann Jason | Director | A-Award | A | Common Stock (right to buy) | 12,004 | 0.00 | — | 12,004 | — | ↗ |
| 2022-06-15 | Hemrajani Rekha | Director | A-Award | A | Stock Option (right to buy) | 12,004 | 0.00 | — | 12,004 | — | ↗ |
| 2022-06-15 | GOODMAN COREY S | Director | A-Award | A | Stock Option (right to buy) | 12,004 | 0.00 | — | 12,004 | — | ↗ |
| 2022-06-15 | Canamasas Itziar | Director | A-Award | A | Stock Option (right to buy) | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2022-04-11 | Canamasas Itziar | Director | A-Award | A | Stock Option (right to buy) | 24,009 | 0.00 | — | 24,009 | — | ↗ |
| 2022-02-07 | GARCIA PETER S | Officer | M-Exempt | A | Common Stock | 6,637 | 4.08 | 27.1K | 16,120 | — | ↗ |
| 2022-02-03 | Pons Jaume | Director / Officer | M-Exempt | A | Common Stock | 12,254 | 1.91 | 23.4K | 468,978 | — | ↗ |
| 2022-01-28 | Pinto Shelly | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,446 | — | ↗ |
| 2021-12-15 | Randolph Sophia | Director / Officer | M-Exempt | A | Common Stock | 11,059 | 1.91 | 21.1K | 188,396 | — | ↗ |
| 2021-12-13 | Lettmann Jason | Director / 10% Owner | S-Sale | D | Common Stock | 299 | 28.37 | 8.5K | 286,197 | — | ↗ |
| 2021-12-13 | LSV Associates, LLC | 10% Owner | S-Sale | D | Common Stock | 1,627 | 25.29 | 41.1K | 290,131 | — | ↗ |
| 2021-12-10 | Lettmann Jason | Director / 10% Owner | S-Sale | D | Common Stock | 967 | 30.77 | 29.8K | 293,942 | — | ↗ |
| 2021-12-10 | LSV Associates, LLC | 10% Owner | S-Sale | D | Common Stock | 12 | 32.16 | 385.92 | 291,758 | — | ↗ |
| 2021-12-09 | Lettmann Jason | Director / 10% Owner | S-Sale | D | Common Stock | 5,751 | 32.06 | 184.4K | 296,820 | — | ↗ |
| 2021-12-09 | LSV Associates, LLC | 10% Owner | S-Sale | D | Common Stock | 11,452 | 31.08 | 355.9K | 2,219,268 | — | ↗ |
| 2021-12-08 | Lettmann Jason | Director / 10% Owner | S-Sale | D | Common Stock | 1,531 | 33.80 | 51.7K | 2,230,720 | — | ↗ |
| 2021-12-08 | LSV Associates, LLC | 10% Owner | S-Sale | D | Common Stock | 1,531 | 33.80 | 51.7K | 2,230,720 | — | ↗ |
| 2021-11-22 | Randolph Sophia | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 4.08 | 122.4K | 179,428 | — | ↗ |
| 2021-10-19 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 2,229 | 55.12 | 122.9K | 444,598 | — | ↗ |
| 2021-10-18 | GARCIA PETER S | Officer | S-Sale | D | Common Stock | 438 | 58.30 | 25.5K | 9,520 | — | ↗ |
| 2021-10-11 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 4,948 | 60.79 | 300.8K | 151,867 | — | ↗ |
| 2021-09-20 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 4,429 | 73.78 | 326.8K | 473,569 | — | ↗ |
| 2021-09-17 | GARCIA PETER S | Officer | S-Sale | D | Common Stock | 1,100 | 81.19 | 89.3K | 9,331 | — | ↗ |
| 2021-09-16 | GARCIA PETER S | Officer | S-Sale | D | Common Stock | 1,426 | 80.43 | 114.7K | 9,331 | — | ↗ |
| 2021-09-10 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 900 | 76.45 | 68.8K | 163,302 | — | ↗ |
| 2021-08-23 | GARCIA PETER S | Officer | S-Sale | D | Common Stock | 18,060 | 72.66 | 1.31M | 46,181 | — | ↗ |
| 2021-08-19 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 1,190 | 62.84 | 74.8K | 480,544 | — | ↗ |
| 2021-08-17 | GARCIA PETER S | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 10,000 | 4.08 | 40.8K | 136,289 | — | ↗ |
| 2021-08-10 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 5,599 | 64.76 | 362.6K | 164,272 | — | ↗ |
| 2021-07-30 | Randolph Sophia | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 58.56 | 5.86M | 100,000 | — | ↗ |
| 2021-07-30 | Pons Jaume | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 225,000 | 58.56 | 13.18M | 225,000 | — | ↗ |
| 2021-07-30 | Pinto Shelly | Officer | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 58.56 | 1.46M | 25,000 | — | ↗ |
| 2021-07-30 | GARCIA PETER S | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 58.56 | 5.86M | 100,000 | — | ↗ |
| 2021-07-19 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 1,300 | 53.62 | 69.7K | 509,946 | — | ↗ |
| 2021-07-12 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 7,087 | 54.86 | 388.8K | 171,889 | — | ↗ |
| 2021-06-21 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 6,347 | 58.06 | 368.5K | 521,599 | — | ↗ |
| 2021-06-11 | Nielsen Jack | Director | A-Award | A | Stock Option (right to buy) | 12,004 | 59.66 | 716.2K | 12,004 | — | ↗ |
| 2021-06-11 | Lettmann Jason | Director | A-Award | A | Stock Option (right to buy) | 12,004 | 59.66 | 716.2K | 12,004 | — | ↗ |
| 2021-06-11 | Hemrajani Rekha | Director | A-Award | A | Stock Option (right to buy) | 12,004 | 59.66 | 716.2K | 12,004 | — | ↗ |
| 2021-06-11 | Graham G. Walmsley | Director | A-Award | A | Stock option (right to buy) | 12,004 | 59.66 | 716.2K | 12,004 | — | ↗ |
| 2021-06-11 | GOODMAN COREY S | Director | A-Award | A | Stock Option (right to buy) | 12,004 | 59.66 | 716.2K | 12,004 | — | ↗ |
| 2021-06-10 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 1,188 | 59.80 | 71.0K | 185,175 | — | ↗ |
| 2021-05-19 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 500 | 54.20 | 27.1K | 544,146 | — | ↗ |
| 2021-05-10 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 956 | 62.79 | 60.0K | 186,436 | — | ↗ |
| 2021-05-03 | Pinto Shelly | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-19 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 5,330 | 56.42 | 300.7K | 556,016 | — | ↗ |
| 2021-04-12 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 2,941 | 60.29 | 177.3K | 194,293 | — | ↗ |
| 2021-03-25 | Pons Jaume | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 0.99 | 9.9K | 561,346 | — | ↗ |
| 2021-03-22 | Pons Jaume | Director / Officer | S-Sale | D | Common Stock | 600 | 70.12 | 42.1K | 551,346 | — | ↗ |
| 2021-03-10 | Randolph Sophia | Director / Officer | S-Sale | D | Common Stock | 1,297 | 73.38 | 95.2K | 207,227 | — | ↗ |
| 2021-01-28 | GARCIA PETER S | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 6,128 | 4.08 | 25.0K | 146,289 | — | ↗ |
| 2021-01-26 | Pons Jaume | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 0.99 | 9.9K | 551,346 | — | ↗ |
| 2020-12-14 | Graham G. Walmsley | Director | P-Purchase | A | Common Stock | 20,000 | 76.00 | 1.52M | 995,000 | — | ↗ |
| 2020-07-21 | Vivo Capital IX, LLC | 10% Owner | C-Conversion | D | Series C Convertible Preferred Stock | 3,158,851 | 0.00 | — | 0 | — | ↗ |
| 2020-07-21 | Pons Jaume | Director / Officer | C-Conversion | D | Series C Convertible Preferred Stock | 5,264 | 0.00 | — | 0 | — | ↗ |
| 2020-07-21 | Pietzke Steffen | Officer | P-Purchase | A | Common Stock | 3,000 | 19.00 | 57.0K | 3,000 | — | ↗ |
| 2020-07-21 | Lettmann Jason | Director / 10% Owner | C-Conversion | A | Common Stock | 1,498,984 | 0.00 | — | 2,023,469 | — | ↗ |
| 2020-07-21 | LSV Associates, LLC | 10% Owner | C-Conversion | A | Common Stock | 1,498,984 | 0.00 | — | 2,023,469 | — | ↗ |
| 2020-07-21 | Hemrajani Rekha | Director | P-Purchase | A | Common Stock | 3,000 | 19.00 | 57.0K | 3,000 | — | ↗ |
| 2020-07-21 | Graham G. Walmsley | Director | C-Conversion | D | Series C Convertible Preferred Stock | 2,105,901 | 0.00 | — | 0 | — | ↗ |
| 2020-07-21 | GOODMAN COREY S | Director / 10% Owner | C-Conversion | A | Common Stock | 3,100,020 | 0.00 | — | 3,969,789 | — | ↗ |
| 2020-07-21 | GARCIA PETER S | Officer | P-Purchase | A | Common Stock | 3,000 | 19.00 | 57.0K | 3,000 | — | ↗ |
| 2020-07-21 | Caffo Nathan | Officer | C-Conversion | A | Common Stock | 10,529 | 0.00 | — | 11,254 | — | ↗ |
| 2020-07-21 | Adelman Robert J | — | C-Conversion | D | Series A Convertible Preferred Stock | 2,398,588 | 0.00 | — | 0 | — | ↗ |
| 2020-07-16 | Vivo Capital IX, LLC | 10% Owner | — | I | Series C Convertible Preferred Stock | 3,158,851 | 0.00 | — | 0 | — | ↗ |
| 2020-07-16 | Randolph Sophia | Officer | — | D | Employee Stock Option (right to buy) | 23,490 | 1.91 | 44.9K | 0 | — | ↗ |
| 2020-07-16 | Pons Jaume | Director / Officer | — | D | Series C Convertible Preferred Stock | 5,264 | 0.00 | — | 0 | — | ↗ |
| 2020-07-16 | Pietzke Steffen | Officer | — | D | Employee Stock Option (right to buy) | 151,961 | 4.08 | 620.0K | 0 | — | ↗ |
| 2020-07-16 | Nielsen Jack | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-16 | Lettmann Jason | Director / 10% Owner | — | I | Series C Convertible Preferred Stock | 38,660 | 0.00 | — | 0 | — | ↗ |
| 2020-07-16 | LSV Associates, LLC | 10% Owner | — | — | Series C Convertible Preferred Stock | 38,660 | 0.00 | — | 0 | I | ↗ |
| 2020-07-16 | Hemrajani Rekha | Director | — | D | Stock Option (right to buy) | 87,378 | 4.81 | 420.3K | 0 | — | ↗ |
| 2020-07-16 | Graham G. Walmsley | Director | A-Award | A | Stock Option (right to buy) | 24,009 | 19.00 | 456.2K | 24,009 | — | ↗ |
| 2020-07-16 | GOODMAN COREY S | Director / 10% Owner | — | I | Series B Convertible Preferred Stock | 15,794 | 0.00 | — | 0 | — | ↗ |
| 2020-07-16 | GARCIA PETER S | Officer | — | D | Employee Stock Option (right to buy) | 29,176 | 4.81 | 140.3K | 0 | — | ↗ |
| 2020-07-16 | Caffo Nathan | Officer | — | D | Employee Stock Option (right to buy) | 100,750 | 1.85 | 186.4K | 0 | — | ↗ |
| 2020-07-16 | Adelman Robert J | — | C-Conversion | D | Series C Convertible Preferred Stock | 1,052,950 | 0.00 | — | 0 | — | ↗ |
| 2020-05-03 | Pinto Shelly | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 62.83 | 7.85M | 125,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
54.23M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jason Lettmann Chief Executive Officer | 724.5K | — | — | 1.45M | 298.9K | — | 2.47M | 58.58% | ↗ |
| 2 | 2025 | Harish Shantharam Chief Financial Officer | 464.5K | — | — | 1.08M | 151.9K | — | 1.70M | 63.76% | ↗ |
| 3 | 2025 | Jaume Pons, Ph.D. Former President and Chief Scientific Officer | 259.2K | — | — | 64.5K | — | 650.0K | 973.7K | 6.63% | ↗ |
| 4 | 2025 | Shelly Wong Senior Vice President, Finance and Chief Accounting Officer | 435.6K | — | — | 361.9K | 142.9K | — | 940.4K | 38.49% | ↗ |
| 5 | 2024 | Jason Lettmann Chief Executive Officer | 700.0K | — | 3.17M | 2.48M | 292.6K | — | 6.64M | 85.05% | ↗ |
| 6 | 2024 | Sophia Randolph, M.D., Ph.D. Former Chief Medical Officer | 468.9K | — | 1.43M | 1.13M | — | 503.9K | 3.53M | 72.44% | ↗ |
| 7 | 2024 | Jaume Pons, Ph.D. Former President and Chief Scientific Officer | 650.0K | — | 950.4K | 1.13M | 288.9K | — | 3.02M | 68.89% | ↗ |
| 8 | 2024 | Peter Garcia Former Chief Financial Officer | 473.6K | — | 792.0K | 951.8K | — | 479.6K | 2.70M | 64.66% | ↗ |
| 9 | 2024 | Shelly Pinto Senior Vice President, Finance and Chief Accounting Officer | 378.8K | 25.0K | 396.0K | 583.0K | 122.4K | — | 1.51M | 65.04% | ↗ |
| 10 | 2024 | Shelly Wong Senior Vice President, Finance and Chief Accounting Officer | 378.8K | 25.0K | 396.0K | 583.0K | 122.4K | — | 1.51M | 65.04% | ↗ |
| 11 | 2023 | Jason Lettmann Chief Executive Officer | 217.3K | — | — | 4.37M | 119.0K | 151.3K | 4.86M | 89.96% | ↗ |
| 12 | 2023 | Jaume Pons, Ph.D. President, Chief Scientific Officer and former Chief Executive Officer | 649.7K | — | 521.5K | 1.22M | 357.4K | — | 2.75M | 63.32% | ↗ |
| 13 | 2023 | Jaume Pons, Ph.D. Former President and Chief Scientific Officer | 649.7K | — | 521.5K | 1.22M | 357.4K | — | 2.75M | 63.32% | ↗ |
| 14 | 2023 | Sophia Randolph, M.D., Ph.D. Chief Medical Officer | 510.0K | — | 199.2K | 461.7K | 204.0K | — | 1.37M | 48.07% | ↗ |
| 15 | 2023 | Sophia Randolph, M.D., Ph.D. Former Chief Medical Officer | 510.0K | — | 199.2K | 461.7K | 204.0K | — | 1.37M | 48.07% | ↗ |
| 16 | 2023 | Peter Garcia Former Chief Financial Officer | 485.5K | — | 187.5K | 435.8K | 194.2K | — | 1.30M | 47.84% | ↗ |
| 17 | 2023 | Peter Garcia Chief Financial Officer | 485.5K | — | 187.5K | 435.8K | 194.2K | — | 1.30M | 47.84% | ↗ |
| 18 | 2022 | Jaume Pons, Ph.D. President, Chief Scientific Officer and former Chief Executive Officer | 583.5K | — | 848.8K | 2.03M | 272.8K | — | 3.73M | 77.07% | ↗ |
| 19 | 2022 | Jaume Pons, Ph.D. Chief Executive Officer and President | 583.5K | — | 848.8K | 2.03M | 272.8K | — | 3.73M | 77.07% | ↗ |
| 20 | 2022 | Sophia Randolph, M.D., Ph.D. Chief Medical Officer | 471.3K | — | 424.4K | 1.02M | 165.9K | — | 2.08M | 69.43% | ↗ |
| 21 | 2022 | Peter Garcia Chief Financial Officer | 466.8K | — | 332.6K | 790.1K | 164.3K | — | 1.75M | 64.01% | ↗ |
| 22 | 2021 | Jaume Pons, Ph.D. Chief Executive Officer and President | 566.5K | — | — | 9.26M | 283.3K | — | 10.11M | 91.60% | ↗ |
| 23 | 2021 | Shelly Pinto Vice President, Finance and Chief Accounting Officer | 226.7K | 75.0K | — | 6.72M | 90.5K | — | 7.12M | 94.49% | ↗ |
| 24 | 2021 | Peter Garcia Chief Financial Officer | 453.2K | — | — | 4.12M | 181.3K | — | 4.75M | 86.65% | ↗ |
| 25 | 2021 | Sophia Randolph, M.D., Ph.D. Chief Medical Officer | 453.2K | — | — | 4.12M | 181.3K | — | 4.75M | 86.65% | ↗ |
| 26 | 2021 | Steffen Pietzke Former Vice President, | 104.8K | — | — | — | — | — | 104.8K | 0.00% | ↗ |
| 27 | 2020 | Jaume Pons, Ph.D. Chief Executive Officer and President | 487.7K | 500.0K | — | 5.95M | 292.8K | — | 7.23M | 82.30% | ↗ |
| 28 | 2020 | Jaume Pons, Ph.D. Chief Executive Officer, President and Director | 487.7K | 500.0K | — | 5.95M | 292.8K | — | 7.23M | 82.30% | ↗ |
| 29 | 2020 | Peter Garcia Chief Financial Officer | 416.8K | 200.0K | — | 2.01M | 200.8K | — | 2.82M | 71.05% | ↗ |
| 30 | 2020 | Sophia Randolph, M.D., Ph.D. Chief Medical Officer and Director | 397.6K | 350.0K | — | 1.82M | 190.9K | — | 2.76M | 65.96% | ↗ |
| 31 | 2020 | Sophia Randolph, M.D., Ph.D. Chief Medical Officer | 397.6K | 350.0K | — | 1.82M | 190.9K | — | 2.76M | 65.96% | ↗ |
| 32 | 2020 | Steffen Pietzke Former Vice President, | 257.3K | 150.0K | — | 994.9K | 123.9K | — | 1.56M | 63.66% | ↗ |
| 33 | 2019 | Jaume Pons, Ph.D. Chief Executive Officer and President | 422.3K | — | — | 134.0K | 147.9K | — | 704.2K | 19.03% | ↗ |
| 34 | 2019 | Jaume Pons, Ph.D. Chief Executive Officer, President and Director | 422.3K | — | — | 134.0K | 147.9K | — | 704.2K | 19.03% | ↗ |
| 35 | 2019 | Sophia Randolph, M.D., Ph.D. Chief Medical Officer | 351.1K | — | — | 40.8K | 105.4K | — | 497.3K | 8.21% | ↗ |
| 36 | 2019 | Sophia Randolph, M.D., Ph.D. Chief Medical Officer and Director | 351.1K | — | — | 40.8K | 105.4K | — | 497.3K | 8.21% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jason W. Lettmann | Chief Executive Officer & Director | 1M | male |
| Harish Shantharam | Chief Financial Officer | 642.9K | male |
| Shelly Pinto | Senior Vice President of Finance & Chief Accounting Officer | 578.5K | female |
| Shelly Wong | Senior Vice President of Finance & Chief Accounting Officer | 578.5K | female |
| Barbara J. Klencke | Chief Medical Officer | 262.6K | — |
| Athanasios Tsiatis | Senior Vice President of Clinical Development | — | — |
| Venita De Almeida | Vice President & Head of Research Program Development | — | female |
| Jeff E. Knight | Chief Development & Operating Officer | — | male |
| Lin Yeong-Liang | Senior Vice President of Drug Safety & Pharmacovigilance | — | — |
| Lisa Sauer | Senior Vice President of Regulatory Affairs & Quality Assurance | — | female |
| Sue Naim | Senior Vice President of Clinical Operations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALXO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
